A recent study conducted in Finland and published in Acta Dermatologica-Venerology finds that rosacea could be related to underlying systemic inflammation.
A recent study conducted in Finland and published in Acta Dermatologica-Venerology finds that rosacea could be related to underlying systemic inflammation. Researchers found that the risk for rosacea, as well as other skin disorders, such as atopic eczema and onychomycosis (toenail fungus), increased with the presence of systemic low-grade inflammation.
Systemic low-grade inflammation is a chronic condition that, while it may not present visible symptoms, contributes to the pathogenesis of many non-communicable diseases, including atherosclerosis, type 2 diabetes, and metabolic syndrome.
The study analyzed data from 1930 participants in the Northern Finland Birth Cohort 1966. It consisted of individuals from 2 Finnish provinces born during that year whose health was followed regularly through questionnaires and clinical surveys regarding their health and lifestyle factors. The researchers closely identified levels of C-reactive protein (CRP), which is commonly used in clinical studies as a strong marker of inflammation. In individuals with slightly elevated blood levels of CRP, participants were 1.7 times more likely to have rosacea than those with normal levels.
The researchers reported, “It is noteworthy that despite the fact that the majority of the study cases had mild disease, we were nevertheless able to detect the associations with inflammation.” A number of factors can impact an individual’s CRP level, such as age, sex, body mass index, and other lifestyle factors. When these factors were accounted for in the study, the risk of rosacea was still greater than in normal individuals, however not at a statistically significant level.
The study also found it important to note that the presence of 1 inflammatory disease exacerbates the risk for others. Given this fact, researchers extrapolated that patients with skin disorders such as rosacea may carry an elevated risk for other non-communicable diseases. Further studies are needed in order to learn more about the relationship between inflammation and specific skin disorders, researchers reported.
In 2010, the National Rosacea Society (NRS) estimated that nearly 16 million Americans were affected by rosacea. “Although medical therapy and proper care have helped millions of Americans control the signs and symptoms of this disorder, the steady growth and aging of the population have raised the incidence of this chronic condition over the past decade,” said Dr. Jonathan Wilkin, former chairman of the NRS medical advisory board in a statement.
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52
April 11th 2024In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
Read More
Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps
April 5th 2024Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
AI Dermatology Mobile Apps Have Critical Efficacy, Safety Gaps, Review Says
March 17th 2024This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.
Read More